Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
05/22/20242:00AMGlobeNewswire Inc.GOGL – First Quarter 2024 ResultsNASDAQ:GOGLGolden Ocean Group Limited
05/22/20242:00AMGlobeNewswire Inc.KBC Group: Update regarding the KBC Group share buyback programmeEU:KBCKBC Groep NV
05/22/20242:00AMBusiness WireSixPeaks Bio AG Debuts With $110 Million in Funding
05/22/20242:00AMGlobeNewswire Inc.KBC Groupe: Mise à jour concernant le programme de rachat d’actions propres de KBC GroupeTG:KDBKBC Groep NV
05/22/20242:00AMGlobeNewswire Inc.Cornish Metals Increases Land Ownership at South Crofty Tin ProjectTSXV:CUSNCornish Metals Inc
05/22/20242:00AMBusiness WireSATO et EM Microelectronic repoussent les limites du possible avec la synergie des technologies RAIN et NFC
05/22/20242:00AMGlobeNewswire Inc.Arbutus to Present Imdusiran Data at EASL Congress 2024NASDAQ:ABUSArbutus Biopharma Corporation
05/22/20242:00AMGlobeNewswire Inc.KBC Groupe: Mise à jour concernant le programme de rachat d’actions propres de KBC GroupeEU:KBCKBC Groep NV
05/22/20242:00AMGlobeNewswire Inc.KBC Group: Update regarding the KBC Group share buyback programmeTG:KDBKBC Groep NV
05/22/20242:00AMGlobeNewswire Inc.GTT: Terms of availability of preparatory documents for the combined general meeting of shareholders on June 12, 2024TG:9TGGaztransport Et Technigaz
05/22/20242:00AMGlobeNewswire Inc.GOGL – First Quarter 2024 ResultsTG:KT31Golden Ocean Group Limited
05/22/20242:00AMGlobeNewswire Inc.GTT : Modalités de mise à disposition des documents préparatoires à l'assemblée générale mixte des actionnaires du 12 juin 2024EU:GTTGaztransport Et Technigaz
05/22/20242:00AMGlobeNewswire Inc.Equinor ASA: Share buy-backTG:DNQEquinor ASA
05/22/20242:00AMGlobeNewswire Inc.GTT : Modalités de mise à disposition des documents préparatoires à l'assemblée générale mixte des actionnaires du 12 juin 2024TG:9TGGaztransport Et Technigaz
05/22/20242:00AMGlobeNewswire Inc.GTT: Terms of availability of preparatory documents for the combined general meeting of shareholders on June 12, 2024EU:GTTGaztransport Et Technigaz
05/22/20241:56AMGlobeNewswire Inc.A Report on the Topics to be Covered in the Webinar
05/22/20241:51AMAlliance NewsAlliance NewsLONDON MARKET EARLY CALL: FTSE 100 called up before UK inflation data
05/22/20241:45AMBusiness WireMADES, a Latecoere Company, recognized by RTX with a Premier Award for performance in 2023TSXV:LATLatin American Minerals Inc
05/22/20241:45AMBusiness WireMADES, une entreprise du groupe Latecoere, reconnue par RTX avec un « Premier Award » pour ses performances en 2023TSXV:LATLatin American Minerals Inc
05/22/20241:40AMPR Newswire (US)COMPUTEX 2024 Preview | Embracing the Era of High-Capacity SSDs
05/22/20241:38AMGlobeNewswire Inc.Novaturas Group earned EUR 34.5 mln. in the first quarter
05/22/20241:33AMAlliance NewsAlliance NewsGET READY: British Land, Close Brothers, M&S, RS, SSE at 0700 BST
05/22/20241:31AMAlliance NewsAlliance NewsAlliance News UK - start of day
05/22/20241:30AMGlobeNewswire Inc.Aalberts N.V.: Aalberts sustained added value margin in challenging market environmentLSE:AALBAalberts
05/22/20241:30AMGlobeNewswire Inc.Aalberts N.V.: Aalberts sustained added value margin in challenging market environmentEU:AALBAalberts NV
05/22/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseasesEU:OSEOSE Immunotherapeutics
05/22/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseasesLSE:0RADOse Immunotherapeutics Sa
05/22/20241:30AMGlobeNewswire Inc.Aalberts N.V.: Aalberts sustained added value margin in challenging market environmentEU:AALBAalberts NV
05/22/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseasesTG:6OPOSE Immunotherapeutics
05/22/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics et Boehringer Ingelheim étendent leur collaboration pour développer des traitements first-in-class dans le cancer et dans les maladies cardiovasculaires, rénales et métaboliquesEU:OSEOSE Immunotherapeutics